|
|
News Breaks
|
December 2, 2011
|
| 07:05 EDT |  | ONCY |
| theflyonthewall.com: | Oncolytics Biotech: Phase 2 clinical trial of REOLYSIN with Gemcitabine | | Oncolytics Biotech announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with gemcitabine, or Gemzar, in patients with advanced pancreatic cancer, or REO 017, indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active. To date, eight patients of 13 evaluable patients in the study had stable disease, or SD, for 12 weeks or longer, for a clinical benefit rate, or complete response, CR + partial response, or PR, PR + SD) of 62%. An additional patient had an unconfirmed PR of less than six weeks. :theflyonthewall.com |
|
|
News For ONCY From The Last 14 Days Check below for free stories on ONCY the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 15, 2012
|
| 07:30 EDT |  | ONCY |
|
|
|
|
|
Subscribe for More Information